104 related articles for article (PubMed ID: 38956425)
1. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis.
Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H
Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425
[TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
3. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P;
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193
[TBL] [Abstract][Full Text] [Related]
4. Postpartum Bleeding in Pregnant Women Receiving SSRIs/SNRIs: New Insights From a Descriptive Observational Study and an Analysis of Data from the FAERS Database.
Perrotta C; Giordano F; Colombo A; Carnovale C; Castiglioni M; Di Bernardo I; Giorgetti F; Pileri P; Clementi E; Viganò C
Clin Ther; 2019 Sep; 41(9):1755-1766. PubMed ID: 31371035
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
[TBL] [Abstract][Full Text] [Related]
7. Risk of abnormal uterine bleeding associated with high-affinity compared with low-affinity serotonin and norepinephrine reuptake inhibitors.
Engler J; Filliter C; Montastruc F; Abenhaim H; Rej S; Renoux C
J Affect Disord; 2024 Apr; 350():813-821. PubMed ID: 38246277
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events.
Lee YC; Lin CH; Lin MS; Lu Y; Chang CH; Lin JW
J Clin Psychiatry; 2016 Jan; 77(1):e1-7. PubMed ID: 26845272
[TBL] [Abstract][Full Text] [Related]
9. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.
Lanteigne A; Sheu YH; Stürmer T; Pate V; Azrael D; Swanson SA; Miller M
CNS Drugs; 2015 Mar; 29(3):245-52. PubMed ID: 25708711
[TBL] [Abstract][Full Text] [Related]
10. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths.
Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL
JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533
[TBL] [Abstract][Full Text] [Related]
11. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study.
Montastruc JL; Rousseau V; de Canecaude C; Roussin A; Montastruc F
Eur J Clin Pharmacol; 2020 Sep; 76(9):1321-1327. PubMed ID: 32483650
[TBL] [Abstract][Full Text] [Related]
12. Apathy symptoms induced by low-dose venlafaxine: Two cases.
Sato S; Sodeyama N; Matsuzaki A; Shiratori Y
Neuropsychopharmacol Rep; 2020 Jun; 40(2):196-197. PubMed ID: 32267090
[TBL] [Abstract][Full Text] [Related]
13. [Hyponatremia associated with SSRI/NRSI: Descriptive and comparative epidemiological study of the incidence rates of the notified cases from the data of the French National Pharmacovigilance Database and the French National Health Insurance].
Revol R; Rault C; Polard E; Bellet F; Guy C
Encephale; 2018 Jun; 44(3):291-296. PubMed ID: 29248119
[TBL] [Abstract][Full Text] [Related]
14. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
Alrasheed M; Hincapie AL; Guo JJ
J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
[TBL] [Abstract][Full Text] [Related]
15. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis.
Gosmann NP; Costa MA; Jaeger MB; Frozi J; Spanemberg L; Manfro GG; Cortese S; Cuijpers P; Pine DS; Salum GA
Psychol Med; 2023 Jul; 53(9):3783-3792. PubMed ID: 37278215
[TBL] [Abstract][Full Text] [Related]
16. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
17. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study.
Leong C; Alessi-Severini S; Enns MW; Nie Y; Sareen J; Bolton J; Prior HJ; Chateau D
J Clin Psychopharmacol; 2017 Jun; 37(3):332-340. PubMed ID: 28383363
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Effects of Selective Serotonin (and Noradrenaline) Reuptake Inhibitors on the Risk of Dementia in Patients with Depression.
Kostev K; Bohlken J; Jacob L
J Alzheimers Dis; 2019; 69(2):577-583. PubMed ID: 31104029
[TBL] [Abstract][Full Text] [Related]
19. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
